RSS Feed
September 7th, 2022 
Awake Goy BRUSSELS—U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation.
The European Commission, which acts as the competition enforcer in the 27-country bloc, said on Tuesday that Illumina’s remedies did not adequately address its concerns.
Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in an EU order to keep Grail separate and appoint independent managers to run the company until the investigation’s conclusion.
“Our in depth investigation confirmed our initial concerns. It showed that Illumina holding a dominant position in NGS systems would have both the ability and the incentive to obstruct rivals,” EU antitrust chief Margrethe Vestager told a news conference, referring to next generation sequencing (NGS)….
The European Commission, which acts as the competition enforcer in the 27-country bloc, said on Tuesday that Illumina’s remedies did not adequately address its concerns.
Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in an EU order to keep Grail separate and appoint independent managers to run the company until the investigation’s conclusion.
“Our in depth investigation confirmed our initial concerns. It showed that Illumina holding a dominant position in NGS systems would have both the ability and the incentive to obstruct rivals,” EU antitrust chief Margrethe Vestager told a news conference, referring to next generation sequencing (NGS)….
Related posts:
Life after Lockdown: Foreword by Rand Paul
How Can We Make Progress After Floyd’s Death?
Liz Gunn further reports police are still surrounding the Whistleblowers’ home after several hours f...
Free books no more: Greek students storm education ministry after publishers suspend scheme (VIDEO)
FDA Notice: Blood Pressure Drugs Recalled After Powerful Opioid Found
Taliban Takeover Alarms The Gulf
Views: 0
Posted in 
Tags: 
